tickrz reports
Gilead Sciences Inc (GILD)
Healthcare | Drugs
74.19  -0.04%
GILD vs DRUGS SECTOR & S&P 500
VALUATION
GILDSECTORS&P 500
P/E RATIO8.443820.18
EV/EBITDA RATIO4.9121.612.15
P/S RATIO3.566.22.14
P/B RATIO3.947.33.29
QUALITY
RETURN ON EQUITY54.34%15.79%13.65%
RETURN ON CAPITAL92.38%19.38%10.09%
NET MARGIN44.53%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
2.74%
PAYOUT RATIO23.82%
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
4 OUT OF 9
DEBT-TO-EQUITY116%
INTEREST COVERAGE14.6x
CURRENT RATIO3.68
GROWTH
5 YR EPS GROWTH41.14%
5 YR SPS GROWTH29.07%
5 YR BPS GROWTH26.37%
Gilead Sciences Inc News
Gilead: Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta
Gilead: Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta
December 10, 23:39:00 UTC

Republican tax bill makes big winners of Amgen, Gilead and other drugmakers
Of all U.S. companies, drugmakers have some of the most cash held outside the country.
December 10, 17:47:56 UTC

Is Gilead Sciences, Inc. a Buy?
The answer is a definite...
December 10, 16:34:00 UTC

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
Kite, a Gilead Company , announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ in patients with refractory large B-cell lymphoma.
December 10, 15:30:00 UTC

Gilead's new drug keeps 56 pct of lymphoma trial patients alive
More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday. Yescarta, approved by the U.S. Food and Drug Administration in October for aggressive large B-cell lymphoma that did not respond to other treatments, is part of a new class known as chimeric antigen receptor T-cell therapies, or CAR-Ts, designed to reprogram the body's own immune cells to recognize and attack malignant cells. Follow-up on 108 patients treated with Yescarta showed that 42 percent remained in remission after a median of 15 months, and 56 percent were still alive, according to research presented in Orlando at the annual meeting of the American Society of Hematology.
December 10, 15:30:00 UTC

Noteworthy Friday Option Activity: UAL, GILD, ABBV
Among the underlying components of the S amp P 500 index we saw noteworthy options trading volume today in United Continental Holdings Inc Symbol UAL where a total of 16 533 contracts have traded so far representing approximately 1 7 million underlying shares That amounts to about 44 2
December 08, 21:11:05 UTC

ETFs with exposure to Gilead Sciences, Inc. : December 8, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Gilead Sciences, Inc. Here are 5 ETFs with the largest exposure to GILD-US. Comparing the performance and risk of Gilead Sciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
December 08, 17:55:14 UTC

Gilead Sciences: Look Who's Shopping!
Shares of Gilead Sciences (GILD) are higher Friday, after it announced its acquisition of Cell Design Labs. Kite Pharma, which Gilead bought earlier this year, already owned some 12% of the firm, so Gilead ...
December 08, 15:48:00 UTC

Why Biotech Stocks May Wait A While Before Feeling The Love
Beleaguered biotech investors will likely have to wait until 2018 to get some much-needed relief, analysts say.
December 08, 14:57:53 UTC

Gilead Sciences to Acquire Cell Design Labs for $567 Million
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
December 08, 14:43:02 UTC

Gilead to buy Cell Design Labs for up to $567 mln
Drugmaker Gilead Sciences Inc said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs. The deal strengthens Gilead's focus on CAR-T drugs, a new class of cancer therapies that involve genetically modifying a patient's own immune cells to better recognize and attack cancer. Gilead said it would make an initial upfront payment to Cell Design of about $175 million and additional payments of up to $322 million upon meeting certain milestones.
December 07, 23:05:00 UTC

Gilead to pop up to $567 million on East Bay 'smart cell' startup
Launched little more than a year ago to produce cancer-fighting cell therapies just outside a tumor cell's door, an Emeryville company will be bought by biotech powerhouse Gilead Sciences Inc. for up to $567 million. The technologies behind Cell Design Labs Inc. — born out of the work of University of California, San Francisco, Professor Wendell Lim — could boost the effectiveness of so-called CAR-T drugs while decreasing the risk of potential side effects from those groundbreaking treatments. The buyout is structured with Cell Design Labs getting about $175 million upfront and up to $322 million paid out to most of the company's shareholders after hitting undisclosed milestones.
December 07, 22:57:31 UTC

Gilead Sciences To Buy Cell Design Labs In $567 Mln Deal
Gilead Sciences To Buy Cell Design Labs In $567 Mln Deal
December 07, 22:37:00 UTC

Gilead Sciences to buy Cell Design Labs for $567 million
Gilead Sciences Inc. said late Thursday it will acquire privately held cellular therapy company Cell Design Labs Inc. for $567 million. The company said it will acquire the 12.2% of Cell Design shares ...
December 07, 22:33:31 UTC

Gilead to buy Cell Design Labs for up to $567 million
Drugmaker Gilead Sciences Inc said on Thursday it had agreed to acquire privately-held Cell Design Labs Inc for up to $567 million to boost its CAR-T cancer drug pipeline. The deal includes shares already ...
December 07, 22:20:37 UTC


Gilead Sciences Inc (GILD)
Healthcare | Drugs
74.19  -0.04%

Gilead: Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta
Gilead: Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta
December 10, 23:39:00 UTC

Republican tax bill makes big winners of Amgen, Gilead and other drugmakers
Of all U.S. companies, drugmakers have some of the most cash held outside the country.
December 10, 17:47:56 UTC

Is Gilead Sciences, Inc. a Buy?
The answer is a definite...
December 10, 16:34:00 UTC

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
Kite, a Gilead Company , announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ in patients with refractory large B-cell lymphoma.
December 10, 15:30:00 UTC

Gilead's new drug keeps 56 pct of lymphoma trial patients alive
More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday. Yescarta, approved by the U.S. Food and Drug Administration in October for aggressive large B-cell lymphoma that did not respond to other treatments, is part of a new class known as chimeric antigen receptor T-cell therapies, or CAR-Ts, designed to reprogram the body's own immune cells to recognize and attack malignant cells. Follow-up on 108 patients treated with Yescarta showed that 42 percent remained in remission after a median of 15 months, and 56 percent were still alive, according to research presented in Orlando at the annual meeting of the American Society of Hematology.
December 10, 15:30:00 UTC

Noteworthy Friday Option Activity: UAL, GILD, ABBV
Among the underlying components of the S amp P 500 index we saw noteworthy options trading volume today in United Continental Holdings Inc Symbol UAL where a total of 16 533 contracts have traded so far representing approximately 1 7 million underlying shares That amounts to about 44 2
December 08, 21:11:05 UTC

ETFs with exposure to Gilead Sciences, Inc. : December 8, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Gilead Sciences, Inc. Here are 5 ETFs with the largest exposure to GILD-US. Comparing the performance and risk of Gilead Sciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
December 08, 17:55:14 UTC

Gilead Sciences: Look Who's Shopping!
Shares of Gilead Sciences (GILD) are higher Friday, after it announced its acquisition of Cell Design Labs. Kite Pharma, which Gilead bought earlier this year, already owned some 12% of the firm, so Gilead ...
December 08, 15:48:00 UTC

Why Biotech Stocks May Wait A While Before Feeling The Love
Beleaguered biotech investors will likely have to wait until 2018 to get some much-needed relief, analysts say.
December 08, 14:57:53 UTC

Gilead Sciences to Acquire Cell Design Labs for $567 Million
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
December 08, 14:43:02 UTC

Gilead to buy Cell Design Labs for up to $567 mln
Drugmaker Gilead Sciences Inc said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs. The deal strengthens Gilead's focus on CAR-T drugs, a new class of cancer therapies that involve genetically modifying a patient's own immune cells to better recognize and attack cancer. Gilead said it would make an initial upfront payment to Cell Design of about $175 million and additional payments of up to $322 million upon meeting certain milestones.
December 07, 23:05:00 UTC

Gilead to pop up to $567 million on East Bay 'smart cell' startup
Launched little more than a year ago to produce cancer-fighting cell therapies just outside a tumor cell's door, an Emeryville company will be bought by biotech powerhouse Gilead Sciences Inc. for up to $567 million. The technologies behind Cell Design Labs Inc. — born out of the work of University of California, San Francisco, Professor Wendell Lim — could boost the effectiveness of so-called CAR-T drugs while decreasing the risk of potential side effects from those groundbreaking treatments. The buyout is structured with Cell Design Labs getting about $175 million upfront and up to $322 million paid out to most of the company's shareholders after hitting undisclosed milestones.
December 07, 22:57:31 UTC

Gilead Sciences To Buy Cell Design Labs In $567 Mln Deal
Gilead Sciences To Buy Cell Design Labs In $567 Mln Deal
December 07, 22:37:00 UTC

Gilead Sciences to buy Cell Design Labs for $567 million
Gilead Sciences Inc. said late Thursday it will acquire privately held cellular therapy company Cell Design Labs Inc. for $567 million. The company said it will acquire the 12.2% of Cell Design shares ...
December 07, 22:33:31 UTC

Gilead to buy Cell Design Labs for up to $567 million
Drugmaker Gilead Sciences Inc said on Thursday it had agreed to acquire privately-held Cell Design Labs Inc for up to $567 million to boost its CAR-T cancer drug pipeline. The deal includes shares already ...
December 07, 22:20:37 UTC